Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $1.15 in the prior trading day, Calidi Biotherapeutics Inc (AMEX: CLDI) closed at $1.17, up 1.74%. In other words, the price has increased by $1.74 from its previous closing price. On the day, 0.13 million shares were traded. CLDI stock price reached its highest trading level at $1.2125 during the session, while it also had its lowest trading level at $1.1203.
Ratios:
Our goal is to gain a better understanding of CLDI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
. In the most recent recommendation for this company, H.C. Wainwright on November 22, 2023, initiated with a Buy rating and assigned the stock a target price of $11.
On October 09, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 ’25 when Camaisa Allan sold 850 shares for $1.46 per share. The transaction valued at 1,237 led to the insider holds 76,952 shares of the business.
Schoeneck James A bought 75,000 shares of CLDI for $150,000 on Aug 21 ’25. The Director now owns 76,134 shares after completing the transaction at $2.00 per share. On Aug 21 ’25, another insider, Poma Eric E, who serves as the Chief Executive Officer of the company, bought 25,000 shares for $2.00 each. As a result, the insider paid 50,000 and bolstered with 25,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDI now has a Market Capitalization of 8386233 and an Enterprise Value of 1774733.
Stock Price History:
The Beta on a monthly basis for CLDI is 1.08, which has changed by -0.91878533 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, CLDI has reached a high of $19.20, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -18.43%, while the 200-Day Moving Average is calculated to be -68.93%.
Shares Statistics:
The stock has traded on average 152.66K shares per day over the past 3-months and 82280 shares per day over the last 10 days, according to various share statistics. A total of 6.91M shares are outstanding, with a floating share count of 5.01M. Insiders hold about 30.08% of the company’s shares, while institutions hold 3.24% stake in the company. Shares short for CLDI as of 1765756800 were 71326 with a Short Ratio of 0.47, compared to 1763078400 on 170321. Therefore, it implies a Short% of Shares Outstanding of 71326 and a Short% of Float of 1.0299999.
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts. Analysts are recommending an EPS of between -$7.44 and -$7.44 for the fiscal current year, implying an average EPS of -$7.44. EPS for the following year is -$5.52, with 1.0 analysts recommending between -$5.52 and -$5.52.
